Angiotensin 1/2 (2-7) and Enhanced SARS-CoV-2 Spike–AXL Binding: Mechanistic Insights from Recent Research

Study Background and Research Question

Since the emergence of the COVID-19 pandemic, the molecular mechanisms mediating SARS-CoV-2 viral entry have been under intense investigation. The virus’s spike protein enables infection by binding to host cell receptors, predominantly angiotensin-converting enzyme 2 (ACE2), but also neuropilin-1 (NRP1) and, notably, AXL—a receptor tyrosine kinase implicated in infection of respiratory cells with low ACE2 expression. Parallel to this, the renin–angiotensin system (RAS) remains central to vascular homeostasis, with its constituent peptides, especially angiotensin-derived fragments, showing diverse regulatory roles. This convergence raises an important question: how do naturally occurring angiotensin peptides influence SARS-CoV-2 spike protein–host receptor interactions?

Key Innovation from the Reference Study

The reference study by Oliveira et al. (Int. J. Mol. Sci. 2025, 26, 6067) provides the first systematic evidence that endogenous angiotensin peptides—specifically those with N-terminal deletions, such as Angiotensin 1/2 (2-7)—potently enhance the binding of SARS-CoV-2 spike protein to the AXL receptor. This effect appears more pronounced for certain truncated angiotensin fragments than for full-length angiotensin II or I, suggesting a structure-activity relationship that could influence both viral pathogenesis and host vascular response. The work positions angiotensin peptide fragments as dynamic modulators at the interface of cardiovascular and infectious disease pathways.

Methods and Experimental Design Insights

The authors employed antibody-based binding assays to quantify interactions between the SARS-CoV-2 spike protein and its receptors (ACE2, NRP1, and AXL) in the presence of various angiotensin peptide fragments. Peptide variants included full-length angiotensin I (1–10), angiotensin II (1–8), and systematically truncated forms such as angiotensin (1–7), angiotensin (1–6), angiotensin III (2–8), angiotensin IV (3–8), and notably, angiotensin (2–7). Site-directed modifications, including amino acid substitutions and phosphorylation at key positions, were also explored to dissect the molecular determinants of spike–receptor binding enhancement. Data were normalized to vehicle controls to assess fold-changes in binding affinity.

Core Findings and Why They Matter

The study’s principal discovery is that certain angiotensin peptide fragments—particularly those resulting from N-terminal deletions—markedly amplify spike–AXL binding. While angiotensin II (1–8) increased spike–AXL binding approximately two-fold, truncated forms such as angiotensin (2–7) and angiotensin IV (3–8) produced even greater effects, with angiotensin IV yielding a 2.7-fold increase (see reference study). In contrast, the full-length angiotensin I (1–10) and peptides with C-terminal deletions showed less pronounced or no enhancement.

Modifications to the tyrosine residue at position 4—either by substitution with valine or phosphorylation—further potentiated the spike–AXL interaction. This points to the critical role of specific amino acid motifs in the functional activity of these peptides. Notably, while the enhancement was initially characterized for AXL, angiotensin IV also increased spike binding to ACE2 and NRP1, underscoring the multifaceted impact of angiotensin fragments on viral entry routes.

These findings are important for two reasons: first, they identify a mechanistic link between the RAS, a cornerstone of blood pressure regulation research, and the molecular mechanisms of SARS-CoV-2 infection; second, they suggest that physiological or pathological shifts in the abundance or processing of angiotensin peptides may influence susceptibility or severity of COVID-19, especially in tissues with variable ACE2 expression.

Comparison with Existing Internal Articles

Multiple recent reviews and analyses corroborate and expand upon these findings. For instance, "Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Interactions" highlights the unique activity of N-terminally truncated fragments, such as Angiotensin 1/2 (2-7), in promoting AXL-mediated viral entry, especially in cell types with low ACE2 expression. Similarly, another recent review details how these peptide fragments, as products of the renin–angiotensin signaling pathway, may serve as critical modulators of both cardiovascular and infectious disease processes. Additionally, strategic perspectives position Angiotensin 1/2 (2-7) as a promising tool for dissecting cross-domain mechanisms in translational research, leveraging its dual roles in vasoconstriction and viral pathogenesis modeling.

Collectively, these sources reinforce the reference study’s conclusion that angiotensin peptide fragments—long studied for their role as vasoconstrictor peptides and in blood pressure regulation research—now warrant scrutiny as potential co-factors in SARS-CoV-2 host cell entry. This convergence of cardiovascular and infectious disease research domains represents a new translational frontier supported by both recent peer-reviewed and internal evidence.

Limitations and Transferability

Despite its robust experimental design, the reference study has several limitations. The work relies primarily on in vitro binding assays, which, while informative about molecular interactions, do not fully replicate the complexity of in vivo systems where multiple proteolytic enzymes, peptide concentrations, and receptor expressions vary dynamically. The physiological relevance of enhanced spike–AXL binding by angiotensin fragments in actual infection scenarios, and the clinical significance of these findings, remain to be established. Additionally, the potential for differential effects across tissue types and patient populations—especially those with comorbidities affecting the RAS—requires further investigation.

Why this cross-domain matters, maturity, and limitations

The intersection of vasoconstrictor peptides and viral entry mechanisms is of high translational interest. The reference study and corroborating internal reviews show that angiotensin 1/2 (2-7), a peptide previously characterized for its role in the regulation of blood pressure and aldosterone release stimulation, also modulates SARS-CoV-2 spike protein–host receptor interactions. This cross-domain bridge is still at an early stage, with in vitro data providing a mechanistic rationale but lacking direct in vivo or clinical correlation. Thus, while the findings are promising for the development of advanced cardiovascular and infectious disease models, caution is warranted in extrapolating to patient outcomes or therapeutic strategies without further validation.

Protocol Parameters

• Peptide concentration: Angiotensin 1/2 (2-7) is commonly used in the low micromolar range (e.g., 1–10 μM) in in vitro receptor binding or signaling assays, as inferred from standard peptide workflow practices and the study design.
• Solubility considerations: Prepare stock solutions in water, ethanol, or DMSO according to the product information (≥46.6 mg/mL in water).
• Storage: For highest purity and stability, store lyophilized peptide at –20°C; prepare fresh working solutions immediately prior to use.
• Receptor binding assay workflow: Incubate cells or receptor-coated plates with peptide for 30–60 minutes prior to addition of spike protein, following conditions similar to those described in the reference study.
• Experimental controls: Always include vehicle and full-length peptide controls to benchmark the activity of truncated fragments such as Angiotensin 1/2 (2-7).

Research Support Resources

Researchers aiming to model or further dissect the role of angiotensin peptide fragments in blood pressure regulation or SARS-CoV-2 spike–receptor binding can utilize high-purity reagents such as Angiotensin 1/2 (2-7) (SKU A1050). With well-validated purity and solubility properties, this ARG-VAL-TYR-ILE-HIS-PRO peptide supports both cardiovascular and infectious disease research workflows. The product is intended strictly for scientific research and should be handled according to recommended guidelines. For broader context or protocol development, investigators may also consult internal reviews and mechanistic analyses linked above.